iMALT One-Year Extension and Close Out Funds

May 2021 Council

Lead Division/Office


Point(s) of Contact

Edward Doo, M.D.; Averell H. Sherker, M.D., FRCPC

Executive Summary

The iMALT clinical intervention trial utilizes a telemetric intervention to alter complications due to immune suppression non-adherence. iMALT was operational when the COVID-19 pandemic adversely affected the enrollment rate. With the gradual lifting of clinical center COVID-19 restrictions, the new projected enrollment completion date is expected to extend beyond the final grant year for this project. This initiative request is for a one-year extension of the iMALT trial in order to preserve the study statistical power and integrity.